By Omar Perez, Head of Medical Diagnostics, US Medical Affairs
As the field of oncology continues to evolve at an unprecedented pace, precision medicine has emerged in the last 20 years and has become part of the standard treatment for some cancers.[1] The global precision medicine market is projected to continue to grow at a 12.1% compound annual growth rate.[2] This groundbreaking approach focuses on tailoring treatment plans for individual patients based on their unique genetic profiles, in one specific instance—biomarkers. At AstraZeneca, we are proud to be at the forefront of precision medicine in oncology. Through patient-centric diagnostics, testing of biomarker advancements[3], and strategic partnerships, we are helping revolutionize the way we combat cancers such as non-small cell lung cancer (NSCLC), breast cancer, and prostate cancer. In this article, we will delve into the importance of biomarker testing, highlight the potential of circulating tumor DNA (ctDNA), discuss collaboration with patient advocacy groups and policymakers, and emphasize the significance of patient empowerment throughout the treatment process.
Putting Patients First
At the heart of precision medicine in oncology lies an approach that acknowledges the uniqueness of each individual, as well as their specific type of cancer. By focusing on patient-centric diagnostics that use robust genetic and molecular biomarker data, we are better equipped to provide tailored treatment strategies. Understanding the patient's medical history, lifestyle factors, and personal preferences allows us to develop a holistic view of their needs. By considering the patient as a whole, from lifestyle to molecular makeup, we can help provide more targeted treatments.
Understanding the Power of Biomarker Testing
Biomarker testing, a method that identifies specific biological characteristics in patients and their tumors, such as genes or proteins, has transformed the cancer treatment landscape by enabling oncologists to identify genetic alterations in tumors. This critical information not only aids in diagnosis on the onset of cancer treatment, but it can be used throughout treatment to help guide treatment decisions.
One of the most exciting advancements in biomarker testing is the utilization of circulating tumor DNA (ctDNA). ctDNA refers to small fragments of tumor DNA that are released into the bloodstream. By analyzing ctDNA, clinicians can gain a comprehensive understanding of a patient's tumor profile, even in cases where obtaining a tissue biopsy may be challenging. This unprecedented progress is aligned with initiatives from industry and academia to bring diagnostic testing to more patients worldwide.3
In non-small cell lung cancer (NSCLC), ctDNA analysis allows for the detection of resistance mutations, enabling early intervention and personalized treatment adjustments. For breast cancer and prostate cancer, ctDNA analysis offers a minimally invasive method to monitor disease progression and response to treatment. This approach may help reduce patient discomfort and provide real-time insights into tumor dynamics, facilitating timely treatment modifications with less burden on patients.
Identifying Allies in the Adoption of Biomarker Testing
To drive widespread adoption of biomarker testing and ensure equitable access to precision medicine, collaboration with patient advocacy groups and policymakers is crucial. These partnerships play a pivotal role in raising awareness, advocating for reimbursement policies, and facilitating the integration of biomarker testing into clinical practice.
Patient advocacy groups provide invaluable support to patients and their families, empowering them with knowledge and resources. By partnering with groups like LUNGevity Foundation and Susan G. Komen on educational initiatives, patient support programs, and community outreach, AstraZeneca has helped foster a sense of empowerment and shared decision-making among patients.
Engaging with policymakers enables the shaping of policies that support biomarker testing and precision medicine. By actively participating in discussions and sharing insights, AstraZeneca hopes to influence regulatory frameworks and guidelines that prioritize biomarker testing and encourage insurers to cover genomic testing. These efforts are essential for ensuring that every patient has access to personalized treatments based on their unique genetic makeup.
Empowering Patients in the Treatment Process
Patient empowerment, from education to counseling, is an underutilized, if not misunderstood,[4] cornerstone of precision medicine. Educating patients about the significance of biomarker testing, its potential benefits, and the role it plays in personalized treatment helps demystify the process. Patient-friendly resources, such as brochures and online platforms, can provide accessible information to help empower patients to make informed decisions. Including a genetic counselor on the patient care team can help patients interpret biomarker test results and guide treatment decisions which in turn may help improve patient care and outcomes. Engaging patients in open and honest conversations also fosters a sense of ownership and empowerment.
With all of these advancements, it’s no wonder that precision medicine has revolutionized the landscape of oncology care. Through patient-centric diagnostics, biomarker testing evolution, and strategic partnerships, AstraZeneca is proud to play a role in advocating for the adoption of precision medicine in cancer care. By prioritizing patient empowerment, fostering collaborations with patient advocacy groups and policymakers, and embracing technological advancements like ctDNA analysis, we can unlock the full potential of precision medicine.
Together, we have the power to transform cancer care and improve outcomes for every patient. Let’s continue to champion precision medicine—through science, advocacy, and policy—and empower patients with the information and resources they need to make informed decisions about their oncology treatment journey with their health care team.
# # #
[1] 20 years of precision medicine in oncology. Lancet. 2021; 397(10287):1781. https://doi.org/10.1016/S0140-6736(21)01099-0.
[2] Precision Medicine Market Size, Trends: Global Demand [2032]. market.us. https://market.us/report/precision-medicine-market/#overview. Published June 2023. Accessed August 2023.
[3] March R. The Changing Landscape of Precision Medicine. AstraZeneca. https://www.astrazeneca.com/what-science-can-do/topics/technologies/precision-medicine-history.html. Published January 2023. Accessed August 2023.
3 March R. The Changing Landscape of Precision Medicine. AstraZeneca. https://www.astrazeneca.com/what-science-can-do/topics/technologies/precision-medicine-history.html. Published January 2023. Accessed August 2023.
[4] Schroll MM, et al. Stakeholders Perceptions of Barriers to Precision Medicine Adoption in the United States. J Pers Med. 2022;12(7):1025. https://doi.org/10.3390/jpm12071025.